• Regeneron annual report for fiscal 2025 highlighted continued reliance on Dupixent, EYLEA HD/EYLEA, Libtayo as core growth drivers.
• Pipeline update flagged nearly 50 clinical candidates across six therapeutic areas, with near-term readouts concentrated in immunology, oncology, rare disease programs.
• Manufacturing execution remained in focus following FDA Complete Response Letters tied to a third-party fill-finish site, with EYLEA HD pre-filled syringe decision targeted for Q2 2026.
• Clinical momentum included plans to submit cemdisiran NDA for myasthenia gravis in Q1 2026.
• Business development featured new rights outside mainland China, Hong Kong, Macau for HS-20094, a dual GLP-1/GIP agonist in Phase 3 development in China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.